Session

Molecular markers for prostate cancer: An update

Poster Session 58

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chairs:
     S. Loeb, New York (US)
     D. Sjoberg, New York (US)
     G.N. Thalmann, Bern (CH)
  • Aims and objectives of this session

    There are at least three different sets of molecular markers for the diagnosis and aggressiveness of prostate cancer on the market. Are the currently available data sufficient for clinical use in the setting of active surveillance or clinical decision making for or against adjuvant treatment? This session will present the latest data on molecular markers for prostate cancer. In addition high quality data on conventional prognostic markers will be discussed.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Molecular markers in prostate cancer: What is currently available?
 S. Loeb, New York (US)
736
Validation of the novel 5-group Gleason grading system: 3+5 disease risk may be overestimated

By: Van den Bergh R.C.N.1, Van Der Kwast T.2, De Jong J.3, Zargar H.4, Murphy D.G.4, Van Der Poel H.G.5

Institutes: 1Royal Melbourne Hospital, Dept. of Urology, Amsterdam, The Netherlands, 2Toronto, Dept. of Pathology, Toronto, Canada, 3NKI, Dept. of Pathology, Amsterdam, The Netherlands, 4Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, 5Amsterdam, Dept. of Urology, Amsterdam, The Netherlands

* 726
Temporal trends in prostate cancer (PCa) risk group stratification following the 2008 United States preventive services task force recommendations

By: Abdollah F.F.H.1, Dalela D.1, Sood A.1, Sammon J.1, Karabon P.1, Meyer C.2, Sun M.2, Choueiri T.3, Menon M.1, Trinh Q.D.2

Institutes: 1Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, 2Brigham and Women’s Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, 3Brigham and Women’s Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

727
Inverse stage migration: Contemporary results of 140.253 North American prostate cancer patients treated with radical prostatectomy from 2004 to 2012

By: Leyh-Bannurah S-R.1, Dell’Oglio P.2, Fisch M.3, Graefen M.1, Karakiewicz P.4, Briganti A.2, Montorsi F.2, Budäus L.1

Institutes: 1Martini-Clinic, Prostate Cancer Center, Hamburg, Germany, 2Urological Research Institute, IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, 3University Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 4University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada

728
Transcriptome-wide expression study reveals biomarker signature with prognostic potential for prostate cancer

By: Horn F.1, Christ-Breulmann S.2, Puppel S-H.2, Buschmann T.2, Reiche K.2, Specht M.2, Bertram C.2, Friedrich M.2, Binder S.2, Blumert C.2, Hackermüller J.3, Kreuz M.4, Löffler M.4, Toma M.I.5, Muders M.5, Baretton G.B.5, Fröhner M.6, Füssel S.6, Wirth M.6

Institutes: 1University of Leipzig, Institute of Clinical Immunology, Leipzig, Germany, 2Fraunhofer Institute of Cell Therapy and Immunology, Dept. of Diagnostics, Leipzig, Germany, 3Helmholtz Centre For Environmental Research, Young Investigator Group Bioinformatics & Transcriptomics, Leipzig, Germany, 4University of Leipzig, Institute For Medical Informatics, Statistics and Epidemiology, Leipzig, Germany, 5University Hospital “Carl Gustav Carus”, Technical University Dresden, Institute of Pathology, Dresden, Germany, 6University Hospital “Carl Gustav Carus”, Technical University Dresden, Dept. of Urology, Dresden, Germany

* 729
Utilization of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy

By: Karnes J.R.1, Choeurng V.2, Howard L.3, De Hoedt A.3, Du Plessis M.2, Yousefi K.2, Lam L.2, Buerki C.2, Trabulsi E.J.4, Dicker A.P.4, Davicioni E.2, Freedland S.J.3, Den R.B.4

Institutes: 1Mayo Clinic, Dept. of Urology, Rochester, United States of America, 2GenomeDx Biosciences, Dept. of Clinical Operations, Vancouver, Canada, 3Duke University, Dept. of Urology, Durham, United States of America, 4Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, United States of America

730
Decipher genomic classifier measured on prostate biopsy predicts 10 year metastasis risk

By: Klein E.1, Neumann S.5, Yousefi K.2, Haddad Z2, Lam L.2, Wang Q.2, Choeurng V.2, Palmer-Aronsten B.2, Buerki C.2, Davicioni E.2, Li J.3, Kattan M.W.3, Stephenson A.J.1, Magi-Galluzzi C.4

Institutes: 1Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, United States of America, 2GenomeDx Biosciences, Dept. of Clinical Operations, Vancouver, Canada, 3Cleveland Clinic, Dept. of Quantitative Health Sciences, Cleveland, United States of America, 4Cleveland Clinic, Dept. of Anatomic Pathology, Cleveland, United States of America, 5Genomedx Biosciences, Dept. of Marketing, Vancouver, Canada

731
The power of a genomic classifier to assess cancer persistence and biochemical failure in patients post-prostatectomy

By: Woodlief T., Rocco B., Ganapathi H., Ogaya G., Mouraviev V., Patel V.

Institutes: Florida Hospital, Global Robotics Institute, Celebration, United States of America

732
CCP-score improves the current risk assessment in newly diagnosed prostate cancer patients

By: Oderda M.1, Cozzi G.2, Barale M.1, Garelli G.1, Gurioli A.1, Daniele L.3, Sapino A.3, Renne G.4, De Cobelli O.2, Gontero P.1

Institutes: 1University of Turin, Dept. of Surgical Sciences/Urology, Turin, Italy, 2Istituto Europeo Di Oncologia, Dept. of Urology, Milan, Italy, 3A.O.U. Città Della Salute E Della Scienza, Dept. of Pathology, Turin, Italy, 4Istituto Europeo Di Oncologia, Dept. of Pathology, Milan, Italy

733
Heterogeneity in circulating tumor cells (CTCs) in blood samples of metastatic castration-resistant prostate cancer (mCRPC) patient: Comparison of isolation techniques

By: Theil G., Weiß C., Fischer K., Schumann A., Fornara P.

Institutes: UKH Universitätsklinikum Halle (Saale), Dept. of Urology and Kidney Transplantation, Halle/Saale, Germany

734
Highly-trained dogs’ olfactory system for detecting biochemical recurrence following radical prostatectomy

By: Taverna G.2, Tidu L.3, Grizzi F.1, Stork B.4, Seveso M.2, Bozzini G.2, Sardella P.3, Latorre G.3, Lughezzani G.5, Buffi N.5, Guazzoni G.5, Mandressi A.2

Institutes: 1Humanitas Research Hospital, Dept. of Immunology and Inflammation, Rozzano, Italy, 2Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, 3Italian Ministry of Defense, Dept. of Veterinary Center, Grosseto, Italy, 4West Shore Urology, Dept. of Urology, Michigan, United States of America, 5Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

735
What is the prognostic impact of nodal tumour burden in patients with a single positive node at final pathology?

By: Nini A.1, Lucianò R.2, Freschi M.2, Fossati N.1, Gandaglia G.1, Castiglione F.3, La Croce G.1, Saitta G.1, Bertini R.1, Doglioni C.2, Montorsi F.1, Briganti A.1

Institutes: 1IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy, 3University Hospitals Leuven, Dept. of Urology, Leuven, Belgium

737
Prognostic value of lymphovascular invasion in robot-assisted radical prostatectomy patients with prostate confined, resection margin negative tumour

By: Kang Y.J.1, Jang W.S.1, Kwon J.K.1, Yoon C.Y.1, Lee J.Y.1, Cho K.S.1, Ham W.S.1, Cho I.R.2, Choi Y.D.1

Institutes: 1Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 2Inje University, College of Medicine, Dept. of Urology, Goyang, South Korea